NCT07245914Active, not recruiting
A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to observe the impact of Pivit on body weight in overweight individuals. Additionally, the study aims to observe the impact of the product on appetite, hunger, cravings, and general well-being via activities and technologies that can successfully and effectively be completed in a home setting. A consumer-driven, decentralized observational clinical research study is therefore well-suited for examining the impact of this product in this population. The study team will examine the outcomes in a broad age-range of adults who have chosen to try this product. The study will incorporate participant reported outcome questionnaires and surveys and at-home body weight measurement using a personal scale. There is no "doctor-patient" relationship as part of this research since the participant as a consumer is making the informed choice to take the product and take part in the observational process with self-reported measures and at-home body weight measurement. Findings from this study will contribute knowledge toward the tolerability and formulation of the plant-derived consumer product and the design of future studies.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 125 (estimated)
- First submitted
- 15 Sept 2025
- Start date
- 30 Jul 2025
- Primary completion date
- 26 Jan 2026
- Lead sponsor
- Olfactive Biosolutions, Inc.
- Diseases
- Obesity
- NCT number
- NCT07245914
What you commit to
- Study type: Observational
- Planned participants: 125
- From 30 Jul 2025 to the primary completion date, 26 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently on or planning to start a fad diet, keto diet, pure carnivore diet, raw food diet, fruitarian diet, liquid diet (does not include vegans or vegetarians)
- Concomitant Conditions and Therapies:
- Any investigational therapies or treatments within 30 days prior to enrollment.
Other illness
- Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
- Any underlying medical conditions or comorbidities that may confound the evaluation of the study outcomes.
- Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
Lab values
- Known hypersensitivity or previous allergic reaction to Cinnamaldehyde, Spearmint Oil, Eugenol, Butyl butyryl lactate, Benzyl acetate, Lauric acid, Sodium-Copper Chlorophyllin, Sunflower Seed Oil, Gelatin, Glycerin
Other
- Any potential participants who:
- Do not have a personal smartphone, internet access, or unwilling to download Chloe.
- GLP-1 receptor agonists and related incretin mimetics, (e.g. semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), sitagliptin (Januvia, Janumet), saxagliptin (Onglyza, Komblglyze), alogliptin (Nesina, Kazano, Oseni), linagliptin (Tradjenta, Jentadueto) or tirzepatide (Mounjaro)
- Currently pregnant, planning to become pregnant in the next 1 month, or breastfeeding
- Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.
Who the study is looking for
- Age 18 years and older
- Has self-reported body mass index (BMI) between 25 and 34.9 kg/m2.
- Interested in learning about weight management and appetite and in trying Pivit product for themselves.
- GLP-1 medication naive or has not taken any GLP-1 inducing weight-loss medications prior to enrollment.
- Willingness to refrain from taking any weight loss supplements during the study.
- Has a personal digital weight scale at home to use during the study.
- In good general health at the time of screening (Investigator discretion).
- Able to read and understand English.
- Able to read, understand, and provide informed consent.
- Able to use a personal smartphone device and download Chloe by People Science.
- Able to receive shipment of the product at an address within the United States.
- Able to complete study assessments over the course of up to 17 weeks.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| People Science Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.